#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Oxidative stress was identified as a hallmark of almost all cardiovascular and neurodegenerative diseases .
2-1	16-25	Oxidative	abstract[2]	new[2]	_	_
2-2	26-32	stress	abstract[2]	new[2]	_	_
2-3	33-36	was	_	_	_	_
2-4	37-47	identified	_	_	_	_
2-5	48-50	as	_	_	_	_
2-6	51-52	a	abstract[3]	new[3]	_	_
2-7	53-61	hallmark	abstract[3]	new[3]	_	_
2-8	62-64	of	abstract[3]	new[3]	_	_
2-9	65-71	almost	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-10	72-75	all	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-11	76-90	cardiovascular	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-12	91-94	and	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-13	95-112	neurodegenerative	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-14	113-121	diseases	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-15	122-123	.	_	_	_	_

#Text=The term oxidative stress describes a condition that is either characterized by increased generation of reactive oxygen and nitrogen species ( RONS ) and/or dysregulated cellular antioxidant defense mechanisms ( e.g. , decreased expression of central antioxidant enzymes ) .
3-1	124-127	The	abstract[5]	new[5]	appos	3-3[7_5]
3-2	128-132	term	abstract[5]	new[5]	_	_
3-3	133-142	oxidative	abstract|abstract[7]	new|giv[7]	coref	10-5[112_7]
3-4	143-149	stress	abstract[7]	giv[7]	_	_
3-5	150-159	describes	_	_	_	_
3-6	160-161	a	abstract[8]	new[8]	ana	4-1[0_8]
3-7	162-171	condition	abstract[8]	new[8]	_	_
3-8	172-176	that	abstract[8]	new[8]	_	_
3-9	177-179	is	abstract[8]	new[8]	_	_
3-10	180-186	either	abstract[8]	new[8]	_	_
3-11	187-200	characterized	abstract[8]	new[8]	_	_
3-12	201-203	by	abstract[8]	new[8]	_	_
3-13	204-213	increased	abstract[8]|event[9]	new[8]|new[9]	_	_
3-14	214-224	generation	abstract[8]|event[9]	new[8]|new[9]	_	_
3-15	225-227	of	abstract[8]|event[9]	new[8]|new[9]	_	_
3-16	228-236	reactive	abstract[8]|event[9]|substance[10]|animal[12]	new[8]|new[9]|new[10]|new[12]	coref	6-3[47_12]
3-17	237-243	oxygen	abstract[8]|event[9]|substance[10]|animal[12]	new[8]|new[9]|new[10]|new[12]	_	_
3-18	244-247	and	abstract[8]|event[9]|animal[12]	new[8]|new[9]|new[12]	_	_
3-19	248-256	nitrogen	abstract[8]|event[9]|animal|animal[12]	new[8]|new[9]|new|new[12]	coref	5-29
3-20	257-264	species	abstract[8]|event[9]|animal[12]	new[8]|new[9]|new[12]	_	_
3-21	265-266	(	abstract[8]	new[8]	_	_
3-22	267-271	RONS	abstract[8]|abstract	new[8]|new	coref	5-1[30_0]
3-23	272-273	)	abstract[8]	new[8]	_	_
3-24	274-280	and/or	abstract[8]	new[8]	_	_
3-25	281-293	dysregulated	abstract[8]|abstract[16]	new[8]|new[16]	appos	3-31[17_16]
3-26	294-302	cellular	abstract[8]|abstract[16]	new[8]|new[16]	_	_
3-27	303-314	antioxidant	abstract[8]|person|abstract[15]|abstract[16]	new[8]|new|new[15]|new[16]	coref	4-18
3-28	315-322	defense	abstract[8]|abstract[15]|abstract[16]	new[8]|new[15]|new[16]	_	_
3-29	323-333	mechanisms	abstract[8]|abstract[16]	new[8]|new[16]	_	_
3-30	334-335	(	_	_	_	_
3-31	336-340	e.g.	abstract[17]	giv[17]	coref	6-15[51_17]
3-32	341-342	,	abstract[17]	giv[17]	_	_
3-33	343-352	decreased	abstract[17]	giv[17]	_	_
3-34	353-363	expression	abstract[17]	giv[17]	_	_
3-35	364-366	of	abstract[17]	giv[17]	_	_
3-36	367-374	central	abstract[17]|abstract[19]	giv[17]|new[19]	_	_
3-37	375-386	antioxidant	abstract[17]|abstract|abstract[19]	giv[17]|new|new[19]	_	_
3-38	387-394	enzymes	abstract[17]|abstract[19]	giv[17]|new[19]	_	_
3-39	395-396	)	_	_	_	_
3-40	397-398	.	_	_	_	_

#Text=This will ultimately cause that tissue , plasma or intercellular fluid run out of low molecular weight antioxidant compounds leading to detrimental alterations of cellular redox state .
4-1	399-403	This	abstract	giv	_	_
4-2	404-408	will	_	_	_	_
4-3	409-419	ultimately	_	_	_	_
4-4	420-425	cause	_	_	_	_
4-5	426-430	that	_	_	_	_
4-6	431-437	tissue	object	new	coref	14-52
4-7	438-439	,	_	_	_	_
4-8	440-446	plasma	substance	new	_	_
4-9	447-449	or	_	_	_	_
4-10	450-463	intercellular	substance[23]	new[23]	_	_
4-11	464-469	fluid	substance[23]	new[23]	_	_
4-12	470-473	run	_	_	_	_
4-13	474-477	out	_	_	_	_
4-14	478-480	of	_	_	_	_
4-15	481-484	low	place[24]|substance[26]	new[24]|new[26]	_	_
4-16	485-494	molecular	place[24]|substance[26]	new[24]|new[26]	_	_
4-17	495-501	weight	place[24]|substance[26]	new[24]|new[26]	_	_
4-18	502-513	antioxidant	person|substance[26]	giv|new[26]	_	_
4-19	514-523	compounds	substance[26]	new[26]	_	_
4-20	524-531	leading	_	_	_	_
4-21	532-534	to	_	_	_	_
4-22	535-546	detrimental	event[27]	new[27]	_	_
4-23	547-558	alterations	event[27]	new[27]	_	_
4-24	559-561	of	event[27]	new[27]	_	_
4-25	562-570	cellular	event[27]|abstract[29]	new[27]|new[29]	_	_
4-26	571-576	redox	event[27]|person|abstract[29]	new[27]|new|new[29]	_	_
4-27	577-582	state	event[27]|abstract[29]	new[27]|new[29]	_	_
4-28	583-584	.	_	_	_	_

#Text=The most abundant biological RONS include superoxide radical , hydrogen peroxide , hydroxyl radical , carbon-centered peroxides and peroxyl radicals , nitric oxide radical ( NO∙ ) , nitrogen dioxide radial , peroxynitrite , and hypochlorite .
5-1	585-588	The	abstract[30]	giv[30]	coref	11-14[0_30]
5-2	589-593	most	abstract[30]	giv[30]	_	_
5-3	594-602	abundant	abstract[30]	giv[30]	_	_
5-4	603-613	biological	abstract[30]	giv[30]	_	_
5-5	614-618	RONS	abstract[30]	giv[30]	_	_
5-6	619-626	include	_	_	_	_
5-7	627-637	superoxide	substance	new	coref	8-2
5-8	638-645	radical	_	_	_	_
5-9	646-647	,	_	_	_	_
5-10	648-656	hydrogen	substance[32]	new[32]	_	_
5-11	657-665	peroxide	substance[32]	new[32]	_	_
5-12	666-667	,	_	_	_	_
5-13	668-676	hydroxyl	abstract	new	_	_
5-14	677-684	radical	_	_	_	_
5-15	685-686	,	_	_	_	_
5-16	687-702	carbon-centered	substance[34]	new[34]	_	_
5-17	703-712	peroxides	substance[34]	new[34]	_	_
5-18	713-716	and	_	_	_	_
5-19	717-724	peroxyl	organization|substance[36]	new|new[36]	_	_
5-20	725-733	radicals	substance[36]	new[36]	_	_
5-21	734-735	,	_	_	_	_
5-22	736-742	nitric	abstract|substance[39]	new|new[39]	coref	7-1
5-23	743-748	oxide	substance|substance[39]	new|new[39]	coref	7-1[53_0]
5-24	749-756	radical	substance[39]	new[39]	_	_
5-25	757-758	(	_	_	_	_
5-26	759-762	NO∙	abstract	new	ana	6-1[46_0]
5-27	763-764	)	_	_	_	_
5-28	765-766	,	_	_	_	_
5-29	767-775	nitrogen	animal|place[43]	giv|new[43]	_	_
5-30	776-783	dioxide	substance|place[43]	new|new[43]	_	_
5-31	784-790	radial	place[43]	new[43]	_	_
5-32	791-792	,	_	_	_	_
5-33	793-806	peroxynitrite	substance	new	_	_
5-34	807-808	,	_	_	_	_
5-35	809-812	and	_	_	_	_
5-36	813-825	hypochlorite	object	new	_	_
5-37	826-827	.	_	_	_	_

#Text=Some of these species were reported to act as cellular messengers and participate in redox signaling mechanisms .
6-1	828-832	Some	abstract[46]	giv[46]	coref	7-4[0_46]
6-2	833-835	of	abstract[46]	giv[46]	_	_
6-3	836-841	these	abstract[46]|animal[47]	giv[46]|giv[47]	coref	10-22[118_47]
6-4	842-849	species	abstract[46]|animal[47]	giv[46]|giv[47]	_	_
6-5	850-854	were	_	_	_	_
6-6	855-863	reported	_	_	_	_
6-7	864-866	to	_	_	_	_
6-8	867-870	act	_	_	_	_
6-9	871-873	as	_	_	_	_
6-10	874-882	cellular	abstract[48]	new[48]	_	_
6-11	883-893	messengers	abstract[48]	new[48]	_	_
6-12	894-897	and	_	_	_	_
6-13	898-909	participate	_	_	_	_
6-14	910-912	in	_	_	_	_
6-15	913-918	redox	abstract|abstract[50]|abstract[51]	new|new[50]|giv[51]	coref|coref|coref	7-31[0_50]|7-30[65_51]|10-8
6-16	919-928	signaling	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
6-17	929-939	mechanisms	abstract[51]	giv[51]	_	_
6-18	940-941	.	_	_	_	_

#Text=Nitric oxide ( NO∙ ) for instance acts as an important vasodilator and inhibitor of platelet activation via formation of nitrosyl-iron enzyme complexes but also provides the basis for wide-spread signaling mechanisms by S-nitros(yl)ation of protein thiol groups as exemplified by suppression of apoptosis by S-nitros(yl)ation of caspases .
7-1	942-948	Nitric	abstract|substance[53]	giv|giv[53]	coref|coref	8-46|8-46[91_53]
7-2	949-954	oxide	substance[53]	giv[53]	_	_
7-3	955-956	(	_	_	_	_
7-4	957-960	NO∙	abstract	giv	_	_
7-5	961-962	)	_	_	_	_
7-6	963-966	for	_	_	_	_
7-7	967-975	instance	_	_	_	_
7-8	976-980	acts	_	_	_	_
7-9	981-983	as	_	_	_	_
7-10	984-986	an	object[55]	new[55]	_	_
7-11	987-996	important	object[55]	new[55]	_	_
7-12	997-1008	vasodilator	object[55]	new[55]	_	_
7-13	1009-1012	and	_	_	_	_
7-14	1013-1022	inhibitor	person[56]	new[56]	_	_
7-15	1023-1025	of	person[56]	new[56]	_	_
7-16	1026-1034	platelet	person[56]|object|event[58]	new[56]|new|new[58]	_	_
7-17	1035-1045	activation	person[56]|event[58]	new[56]|new[58]	_	_
7-18	1046-1049	via	_	_	_	_
7-19	1050-1059	formation	event[59]	new[59]	coref	10-31[121_59]
7-20	1060-1062	of	event[59]	new[59]	_	_
7-21	1063-1076	nitrosyl-iron	event[59]|place|object[62]	new[59]|new|new[62]	_	_
7-22	1077-1083	enzyme	event[59]|substance|object[62]	new[59]|new|new[62]	_	_
7-23	1084-1093	complexes	event[59]|object[62]	new[59]|new[62]	_	_
7-24	1094-1097	but	_	_	_	_
7-25	1098-1102	also	_	_	_	_
7-26	1103-1111	provides	_	_	_	_
7-27	1112-1115	the	abstract[63]	new[63]	_	_
7-28	1116-1121	basis	abstract[63]	new[63]	_	_
7-29	1122-1125	for	abstract[63]	new[63]	_	_
7-30	1126-1137	wide-spread	abstract[63]|abstract[65]	new[63]|giv[65]	_	_
7-31	1138-1147	signaling	abstract[63]|abstract|abstract[65]	new[63]|giv|giv[65]	coref	10-8[114_0]
7-32	1148-1158	mechanisms	abstract[63]|abstract[65]	new[63]|giv[65]	_	_
7-33	1159-1161	by	abstract[63]|abstract[65]	new[63]|giv[65]	_	_
7-34	1162-1179	S-nitros(yl)ation	abstract[63]|abstract[65]|substance[66]	new[63]|giv[65]|new[66]	_	_
7-35	1180-1182	of	abstract[63]|abstract[65]|substance[66]	new[63]|giv[65]|new[66]	_	_
7-36	1183-1190	protein	abstract[63]|abstract[65]|substance[66]|substance|person[69]	new[63]|giv[65]|new[66]|new|new[69]	_	_
7-37	1191-1196	thiol	abstract[63]|abstract[65]|substance[66]|organization|person[69]	new[63]|giv[65]|new[66]|new|new[69]	_	_
7-38	1197-1203	groups	abstract[63]|abstract[65]|substance[66]|person[69]	new[63]|giv[65]|new[66]|new[69]	_	_
7-39	1204-1206	as	_	_	_	_
7-40	1207-1218	exemplified	_	_	_	_
7-41	1219-1221	by	_	_	_	_
7-42	1222-1233	suppression	event[70]	new[70]	_	_
7-43	1234-1236	of	event[70]	new[70]	_	_
7-44	1237-1246	apoptosis	event[70]|abstract	new[70]|new	_	_
7-45	1247-1249	by	event[70]	new[70]	_	_
7-46	1250-1267	S-nitros(yl)ation	event[70]|substance[72]	new[70]|new[72]	_	_
7-47	1268-1270	of	event[70]|substance[72]	new[70]|new[72]	_	_
7-48	1271-1279	caspases	event[70]|substance[72]|substance	new[70]|new[72]|new	_	_
7-49	1280-1281	.	_	_	_	_

#Text=The superoxide radical anion ( O2∙− ) can be formed from different sources such as xanthine oxidase , NADPH ( nicotinamide adenine dinucleotide phosphate ) oxidases , uncoupled NO synthases and the mitochondrial respiratory chain , and represent in many ways a direct antagonist of nitric oxide as shown by the famous experiment by Gryglewski et al. .
8-1	1282-1285	The	substance[75]	new[75]	_	_
8-2	1286-1296	superoxide	substance|substance[75]	giv|new[75]	coref	9-4
8-3	1297-1304	radical	substance[75]	new[75]	_	_
8-4	1305-1310	anion	substance[75]	new[75]	_	_
8-5	1311-1312	(	_	_	_	_
8-6	1313-1317	O2∙−	abstract	new	_	_
8-7	1318-1319	)	_	_	_	_
8-8	1320-1323	can	_	_	_	_
8-9	1324-1326	be	_	_	_	_
8-10	1327-1333	formed	_	_	_	_
8-11	1334-1338	from	_	_	_	_
8-12	1339-1348	different	substance[77]	new[77]	_	_
8-13	1349-1356	sources	substance[77]	new[77]	_	_
8-14	1357-1361	such	substance[77]	new[77]	_	_
8-15	1362-1364	as	substance[77]	new[77]	_	_
8-16	1365-1373	xanthine	substance[77]|plant|abstract[79]	new[77]|new|new[79]	_	_
8-17	1374-1381	oxidase	substance[77]|abstract[79]	new[77]|new[79]	_	_
8-18	1382-1383	,	substance[77]	new[77]	_	_
8-19	1384-1389	NADPH	substance[77]|substance|abstract[85]	new[77]|new|new[85]	_	_
8-20	1390-1391	(	substance[77]|abstract[85]	new[77]|new[85]	_	_
8-21	1392-1404	nicotinamide	substance[77]|substance|substance[84]|abstract[85]	new[77]|new|new[84]|new[85]	_	_
8-22	1405-1412	adenine	substance[77]|substance|substance[84]|abstract[85]	new[77]|new|new[84]|new[85]	_	_
8-23	1413-1425	dinucleotide	substance[77]|abstract|substance[84]|abstract[85]	new[77]|new|new[84]|new[85]	_	_
8-24	1426-1435	phosphate	substance[77]|substance[84]|abstract[85]	new[77]|new[84]|new[85]	_	_
8-25	1436-1437	)	substance[77]|abstract[85]	new[77]|new[85]	_	_
8-26	1438-1446	oxidases	substance[77]|abstract[85]	new[77]|new[85]	_	_
8-27	1447-1448	,	substance[77]	new[77]	_	_
8-28	1449-1458	uncoupled	substance[77]|abstract[87]	new[77]|new[87]	_	_
8-29	1459-1461	NO	substance[77]|substance|abstract[87]	new[77]|new|new[87]	_	_
8-30	1462-1471	synthases	substance[77]|abstract[87]	new[77]|new[87]	_	_
8-31	1472-1475	and	substance[77]	new[77]	_	_
8-32	1476-1479	the	substance[77]|abstract[88]	new[77]|new[88]	_	_
8-33	1480-1493	mitochondrial	substance[77]|abstract[88]	new[77]|new[88]	_	_
8-34	1494-1505	respiratory	substance[77]|abstract[88]	new[77]|new[88]	_	_
8-35	1506-1511	chain	substance[77]|abstract[88]	new[77]|new[88]	_	_
8-36	1512-1513	,	_	_	_	_
8-37	1514-1517	and	_	_	_	_
8-38	1518-1527	represent	_	_	_	_
8-39	1528-1530	in	_	_	_	_
8-40	1531-1535	many	_	_	_	_
8-41	1536-1540	ways	_	_	_	_
8-42	1541-1542	a	person[89]	new[89]	_	_
8-43	1543-1549	direct	person[89]	new[89]	_	_
8-44	1550-1560	antagonist	person[89]	new[89]	_	_
8-45	1561-1563	of	person[89]	new[89]	_	_
8-46	1564-1570	nitric	person[89]|abstract|substance[91]	new[89]|giv|giv[91]	_	_
8-47	1571-1576	oxide	person[89]|substance[91]	new[89]|giv[91]	_	_
8-48	1577-1579	as	_	_	_	_
8-49	1580-1585	shown	_	_	_	_
8-50	1586-1588	by	_	_	_	_
8-51	1589-1592	the	event[92]	new[92]	_	_
8-52	1593-1599	famous	event[92]	new[92]	_	_
8-53	1600-1610	experiment	event[92]	new[92]	_	_
8-54	1611-1613	by	event[92]	new[92]	_	_
8-55	1614-1624	Gryglewski	event[92]|person	new[92]|new	_	_
8-56	1625-1627	et	event[92]	new[92]	_	_
8-57	1628-1631	al.	event[92]	new[92]	_	_
8-58	1632-1633	.	_	_	_	_

#Text=The existence of superoxide dismutases ( mitochondrial MnSOD and cytosolic/extracellular Cu , Zn-SOD ) implies that superoxide may be harmful for the cell , which is supported by the fact that deficiency in MnSOD is lethal and deficiency in Cu , Zn-SOD renders mice susceptible to cardiovascular and neuronal complications .
9-1	1634-1637	The	abstract[94]	new[94]	_	_
9-2	1638-1647	existence	abstract[94]	new[94]	_	_
9-3	1648-1650	of	abstract[94]	new[94]	_	_
9-4	1651-1661	superoxide	abstract[94]|substance|object[96]	new[94]|giv|new[96]	appos|coref	9-7[98_96]|9-17
9-5	1662-1672	dismutases	abstract[94]|object[96]	new[94]|new[96]	_	_
9-6	1673-1674	(	_	_	_	_
9-7	1675-1688	mitochondrial	abstract[97]|object[98]	new[97]|giv[98]	coref	9-34[0_97]
9-8	1689-1694	MnSOD	abstract[97]|object[98]	new[97]|giv[98]	_	_
9-9	1695-1698	and	object[98]	giv[98]	_	_
9-10	1699-1722	cytosolic/extracellular	object[98]|person[99]	giv[98]|new[99]	coref	9-40[0_99]
9-11	1723-1725	Cu	object[98]|person[99]	giv[98]|new[99]	_	_
9-12	1726-1727	,	_	_	_	_
9-13	1728-1734	Zn-SOD	abstract	new	coref	9-42
9-14	1735-1736	)	_	_	_	_
9-15	1737-1744	implies	_	_	_	_
9-16	1745-1749	that	_	_	_	_
9-17	1750-1760	superoxide	substance	giv	coref	12-13
9-18	1761-1764	may	_	_	_	_
9-19	1765-1767	be	_	_	_	_
9-20	1768-1775	harmful	_	_	_	_
9-21	1776-1779	for	_	_	_	_
9-22	1780-1783	the	animal[102]	new[102]	coref	14-22[0_102]
9-23	1784-1788	cell	animal[102]	new[102]	_	_
9-24	1789-1790	,	_	_	_	_
9-25	1791-1796	which	_	_	_	_
9-26	1797-1799	is	_	_	_	_
9-27	1800-1809	supported	_	_	_	_
9-28	1810-1812	by	_	_	_	_
9-29	1813-1816	the	abstract[103]	new[103]	_	_
9-30	1817-1821	fact	abstract[103]	new[103]	_	_
9-31	1822-1826	that	abstract[103]	new[103]	_	_
9-32	1827-1837	deficiency	abstract[103]|abstract[104]	new[103]|new[104]	coref	9-38[106_104]
9-33	1838-1840	in	abstract[103]|abstract[104]	new[103]|new[104]	_	_
9-34	1841-1846	MnSOD	abstract[103]|abstract[104]|abstract	new[103]|new[104]|giv	_	_
9-35	1847-1849	is	abstract[103]	new[103]	_	_
9-36	1850-1856	lethal	abstract[103]	new[103]	_	_
9-37	1857-1860	and	abstract[103]	new[103]	_	_
9-38	1861-1871	deficiency	abstract[103]|abstract[106]	new[103]|giv[106]	_	_
9-39	1872-1874	in	abstract[103]|abstract[106]	new[103]|giv[106]	_	_
9-40	1875-1877	Cu	abstract[103]|abstract[106]|person	new[103]|giv[106]|giv	_	_
9-41	1878-1879	,	abstract[103]|abstract[106]	new[103]|giv[106]	_	_
9-42	1880-1886	Zn-SOD	abstract[103]|abstract[106]|abstract	new[103]|giv[106]|giv	_	_
9-43	1887-1894	renders	abstract[103]	new[103]	_	_
9-44	1895-1899	mice	abstract[103]|animal	new[103]|new	_	_
9-45	1900-1911	susceptible	abstract[103]	new[103]	_	_
9-46	1912-1914	to	_	_	_	_
9-47	1915-1929	cardiovascular	abstract[110]	new[110]	_	_
9-48	1930-1933	and	abstract[110]	new[110]	_	_
9-49	1934-1942	neuronal	abstract[110]	new[110]	_	_
9-50	1943-1956	complications	abstract[110]	new[110]	_	_
9-51	1957-1958	.	_	_	_	_

#Text=Since the transition between oxidative stress and redox signaling is a thin line , the exact knowledge of the identity of formed species , the cellular and subcellular localization of their formation , as well as their time duration and concentration , are of high clinical and pharmacological importance .
10-1	1959-1964	Since	_	_	_	_
10-2	1965-1968	the	abstract[111]	new[111]	coref	10-11[115_111]
10-3	1969-1979	transition	abstract[111]	new[111]	_	_
10-4	1980-1987	between	abstract[111]	new[111]	_	_
10-5	1988-1997	oxidative	abstract[111]|abstract[112]	new[111]|giv[112]	coref	13-14[159_112]
10-6	1998-2004	stress	abstract[111]|abstract[112]	new[111]|giv[112]	_	_
10-7	2005-2008	and	abstract[111]	new[111]	_	_
10-8	2009-2014	redox	abstract[111]|abstract|abstract[114]	new[111]|giv|giv[114]	_	_
10-9	2015-2024	signaling	abstract[111]|abstract[114]	new[111]|giv[114]	_	_
10-10	2025-2027	is	_	_	_	_
10-11	2028-2029	a	abstract[115]	giv[115]	_	_
10-12	2030-2034	thin	abstract[115]	giv[115]	_	_
10-13	2035-2039	line	abstract[115]	giv[115]	_	_
10-14	2040-2041	,	_	_	_	_
10-15	2042-2045	the	abstract[116]	new[116]	_	_
10-16	2046-2051	exact	abstract[116]	new[116]	_	_
10-17	2052-2061	knowledge	abstract[116]	new[116]	_	_
10-18	2062-2064	of	abstract[116]	new[116]	_	_
10-19	2065-2068	the	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-20	2069-2077	identity	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-21	2078-2080	of	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-22	2081-2087	formed	abstract[116]|abstract[117]|animal[118]	new[116]|new[117]|giv[118]	ana	10-31[0_118]
10-23	2088-2095	species	abstract[116]|abstract[117]|animal[118]	new[116]|new[117]|giv[118]	_	_
10-24	2096-2097	,	_	_	_	_
10-25	2098-2101	the	abstract[119]	new[119]	_	_
10-26	2102-2110	cellular	abstract[119]	new[119]	_	_
10-27	2111-2114	and	abstract[119]	new[119]	_	_
10-28	2115-2126	subcellular	abstract[119]	new[119]	_	_
10-29	2127-2139	localization	abstract[119]	new[119]	_	_
10-30	2140-2142	of	abstract[119]	new[119]	_	_
10-31	2143-2148	their	abstract[119]|animal|event[121]	new[119]|giv|giv[121]	ana|coref	10-37|12-12[141_121]
10-32	2149-2158	formation	abstract[119]|event[121]	new[119]|giv[121]	_	_
10-33	2159-2160	,	_	_	_	_
10-34	2161-2163	as	_	_	_	_
10-35	2164-2168	well	_	_	_	_
10-36	2169-2171	as	_	_	_	_
10-37	2172-2177	their	animal|time[123]|time[124]	giv|new[123]|new[124]	_	_
10-38	2178-2182	time	time[123]|time[124]	new[123]|new[124]	_	_
10-39	2183-2191	duration	time[124]	new[124]	_	_
10-40	2192-2195	and	_	_	_	_
10-41	2196-2209	concentration	abstract	new	_	_
10-42	2210-2211	,	_	_	_	_
10-43	2212-2215	are	_	_	_	_
10-44	2216-2218	of	_	_	_	_
10-45	2219-2223	high	abstract[126]	new[126]	_	_
10-46	2224-2232	clinical	abstract[126]	new[126]	_	_
10-47	2233-2236	and	abstract[126]	new[126]	_	_
10-48	2237-2252	pharmacological	abstract[126]	new[126]	_	_
10-49	2253-2263	importance	abstract[126]	new[126]	_	_
10-50	2264-2265	.	_	_	_	_

#Text=With our previous work , we have stressed that the traditional or old RONS assays are not necessarily inferior as compared to up-to-date or even cutting-edge assays and at least have their specific features and application spectra .
11-1	2266-2270	With	_	_	_	_
11-2	2271-2274	our	person|abstract[128]	acc|new[128]	ana	11-6
11-3	2275-2283	previous	abstract[128]	new[128]	_	_
11-4	2284-2288	work	abstract[128]	new[128]	_	_
11-5	2289-2290	,	_	_	_	_
11-6	2291-2293	we	person	giv	ana	12-6
11-7	2294-2298	have	_	_	_	_
11-8	2299-2307	stressed	_	_	_	_
11-9	2308-2312	that	_	_	_	_
11-10	2313-2316	the	abstract[131]	new[131]	coref	11-23[132_131]
11-11	2317-2328	traditional	abstract[131]	new[131]	_	_
11-12	2329-2331	or	abstract[131]	new[131]	_	_
11-13	2332-2335	old	abstract[131]	new[131]	_	_
11-14	2336-2340	RONS	abstract|abstract[131]	giv|new[131]	_	_
11-15	2341-2347	assays	abstract[131]	new[131]	_	_
11-16	2348-2351	are	_	_	_	_
11-17	2352-2355	not	_	_	_	_
11-18	2356-2367	necessarily	_	_	_	_
11-19	2368-2376	inferior	_	_	_	_
11-20	2377-2379	as	_	_	_	_
11-21	2380-2388	compared	_	_	_	_
11-22	2389-2391	to	_	_	_	_
11-23	2392-2402	up-to-date	abstract[132]	giv[132]	ana	11-32[0_132]
11-24	2403-2405	or	abstract[132]	giv[132]	_	_
11-25	2406-2410	even	abstract[132]	giv[132]	_	_
11-26	2411-2423	cutting-edge	abstract[132]	giv[132]	_	_
11-27	2424-2430	assays	abstract[132]	giv[132]	_	_
11-28	2431-2434	and	_	_	_	_
11-29	2435-2437	at	_	_	_	_
11-30	2438-2443	least	_	_	_	_
11-31	2444-2448	have	_	_	_	_
11-32	2449-2454	their	abstract|abstract[134]	giv|new[134]	_	_
11-33	2455-2463	specific	abstract[134]	new[134]	_	_
11-34	2464-2472	features	abstract[134]	new[134]	_	_
11-35	2473-2476	and	_	_	_	_
11-36	2477-2488	application	abstract|abstract[136]	new|new[136]	_	_
11-37	2489-2496	spectra	abstract[136]	new[136]	_	_
11-38	2497-2498	.	_	_	_	_

#Text=With the present studies , we evaluated the specific probe for mitochondrial superoxide formation , mitochondria-targeted , triphenylphosphonium-linked hydroethidium ( mitoSOX ) , for its usefulness in the detection of mitochondrial superoxide formation ex vivo/in vivo and compared this high-performance/pressure liquid chromatography ( HPLC)-based assay with two alternative/traditional methods .
12-1	2499-2503	With	_	_	_	_
12-2	2504-2507	the	abstract[137]	new[137]	_	_
12-3	2508-2515	present	abstract[137]	new[137]	_	_
12-4	2516-2523	studies	abstract[137]	new[137]	_	_
12-5	2524-2525	,	_	_	_	_
12-6	2526-2528	we	person	giv	ana	13-5
12-7	2529-2538	evaluated	_	_	_	_
12-8	2539-2542	the	object[139]	new[139]	appos	12-16[142_139]
12-9	2543-2551	specific	object[139]	new[139]	_	_
12-10	2552-2557	probe	object[139]	new[139]	_	_
12-11	2558-2561	for	object[139]	new[139]	_	_
12-12	2562-2575	mitochondrial	object[139]|event[141]	new[139]|giv[141]	coref	12-31[148_141]
12-13	2576-2586	superoxide	object[139]|substance|event[141]	new[139]|giv|giv[141]	coref	12-32
12-14	2587-2596	formation	object[139]|event[141]	new[139]|giv[141]	_	_
12-15	2597-2598	,	_	_	_	_
12-16	2599-2620	mitochondria-targeted	object[142]	giv[142]	_	_
12-17	2621-2622	,	object[142]	giv[142]	_	_
12-18	2623-2650	triphenylphosphonium-linked	object[142]	giv[142]	_	_
12-19	2651-2664	hydroethidium	object[142]	giv[142]	_	_
12-20	2665-2666	(	_	_	_	_
12-21	2667-2674	mitoSOX	abstract	new	ana	12-25
12-22	2675-2676	)	_	_	_	_
12-23	2677-2678	,	_	_	_	_
12-24	2679-2682	for	_	_	_	_
12-25	2683-2686	its	abstract|abstract[145]	giv|new[145]	coref	14-42[178_0]
12-26	2687-2697	usefulness	abstract[145]	new[145]	_	_
12-27	2698-2700	in	abstract[145]	new[145]	_	_
12-28	2701-2704	the	abstract[145]|abstract[146]	new[145]|new[146]	coref	14-19[169_146]
12-29	2705-2714	detection	abstract[145]|abstract[146]	new[145]|new[146]	_	_
12-30	2715-2717	of	abstract[145]|abstract[146]	new[145]|new[146]	_	_
12-31	2718-2731	mitochondrial	abstract[145]|abstract[146]|event[148]	new[145]|new[146]|giv[148]	_	_
12-32	2732-2742	superoxide	abstract[145]|abstract[146]|substance|event[148]	new[145]|new[146]|giv|giv[148]	coref	14-19
12-33	2743-2752	formation	abstract[145]|abstract[146]|event[148]	new[145]|new[146]|giv[148]	_	_
12-34	2753-2755	ex	abstract[145]|abstract[146]|event[148]	new[145]|new[146]|giv[148]	_	_
12-35	2756-2763	vivo/in	abstract[145]|abstract[146]|event[148]|person	new[145]|new[146]|giv[148]|new	_	_
12-36	2764-2768	vivo	abstract	new	_	_
12-37	2769-2772	and	_	_	_	_
12-38	2773-2781	compared	_	_	_	_
12-39	2782-2786	this	object[153]	new[153]	_	_
12-40	2787-2812	high-performance/pressure	object[152]|object[153]	new[152]|new[153]	_	_
12-41	2813-2819	liquid	substance|object[152]|object[153]	new|new[152]|new[153]	_	_
12-42	2820-2834	chromatography	object[152]|object[153]	new[152]|new[153]	_	_
12-43	2835-2836	(	object[153]	new[153]	_	_
12-44	2837-2848	HPLC)-based	object[153]	new[153]	_	_
12-45	2849-2854	assay	object[153]	new[153]	_	_
12-46	2855-2859	with	_	_	_	_
12-47	2860-2863	two	abstract[154]	new[154]	_	_
12-48	2864-2887	alternative/traditional	abstract[154]	new[154]	_	_
12-49	2888-2895	methods	abstract[154]	new[154]	_	_
12-50	2896-2897	.	_	_	_	_

#Text=For this purpose , we used three different animal models with well established oxidative stress burden , namely diabetic , hypertensive and nitrate tolerant rats .
13-1	2898-2901	For	_	_	_	_
13-2	2902-2906	this	abstract[155]	new[155]	_	_
13-3	2907-2914	purpose	abstract[155]	new[155]	_	_
13-4	2915-2916	,	_	_	_	_
13-5	2917-2919	we	person	giv	ana	14-25
13-6	2920-2924	used	_	_	_	_
13-7	2925-2930	three	abstract[158]	new[158]	_	_
13-8	2931-2940	different	abstract[158]	new[158]	_	_
13-9	2941-2947	animal	animal|abstract[158]	new|new[158]	_	_
13-10	2948-2954	models	abstract[158]	new[158]	_	_
13-11	2955-2959	with	abstract[158]	new[158]	_	_
13-12	2960-2964	well	abstract[158]|abstract[160]	new[158]|new[160]	_	_
13-13	2965-2976	established	abstract[158]|abstract[160]	new[158]|new[160]	_	_
13-14	2977-2986	oxidative	abstract[158]|abstract[159]|abstract[160]	new[158]|giv[159]|new[160]	_	_
13-15	2987-2993	stress	abstract[158]|abstract[159]|abstract[160]	new[158]|giv[159]|new[160]	_	_
13-16	2994-3000	burden	abstract[158]|abstract[160]	new[158]|new[160]	_	_
13-17	3001-3002	,	_	_	_	_
13-18	3003-3009	namely	animal[161]	new[161]	_	_
13-19	3010-3018	diabetic	animal[161]	new[161]	_	_
13-20	3019-3020	,	animal[161]	new[161]	_	_
13-21	3021-3033	hypertensive	animal[161]	new[161]	_	_
13-22	3034-3037	and	animal[161]	new[161]	_	_
13-23	3038-3045	nitrate	animal[161]	new[161]	_	_
13-24	3046-3054	tolerant	animal[161]	new[161]	_	_
13-25	3055-3059	rats	animal[161]	new[161]	_	_
13-26	3060-3061	.	_	_	_	_

#Text=Given the recent report by Xiao & Meierhofer raising doubts about the reliable use of hydroethidium-based probes for superoxide detection in cell culture , we think that our present data are of interest for all researchers using hydroethidium-based probes , but especially mitoSOX , in cell culture , isolated mitochondria and tissue samples .
14-1	3062-3067	Given	_	_	_	_
14-2	3068-3071	the	abstract[162]	new[162]	_	_
14-3	3072-3078	recent	abstract[162]	new[162]	_	_
14-4	3079-3085	report	abstract[162]	new[162]	_	_
14-5	3086-3088	by	abstract[162]	new[162]	_	_
14-6	3089-3093	Xiao	abstract[162]|person	new[162]|new	_	_
14-7	3094-3095	&	abstract[162]|person[164]	new[162]|new[164]	_	_
14-8	3096-3106	Meierhofer	abstract[162]|person[164]	new[162]|new[164]	_	_
14-9	3107-3114	raising	abstract[162]	new[162]	_	_
14-10	3115-3121	doubts	abstract[162]|abstract[165]	new[162]|new[165]	_	_
14-11	3122-3127	about	abstract[162]|abstract[165]	new[162]|new[165]	_	_
14-12	3128-3131	the	abstract[162]|abstract[165]|abstract[166]	new[162]|new[165]|new[166]	_	_
14-13	3132-3140	reliable	abstract[162]|abstract[165]|abstract[166]	new[162]|new[165]|new[166]	_	_
14-14	3141-3144	use	abstract[162]|abstract[165]|abstract[166]	new[162]|new[165]|new[166]	_	_
14-15	3145-3147	of	abstract[162]|abstract[165]|abstract[166]	new[162]|new[165]|new[166]	_	_
14-16	3148-3167	hydroethidium-based	abstract[162]|abstract[165]|abstract[166]|object[167]	new[162]|new[165]|new[166]|new[167]	coref	14-38[176_167]
14-17	3168-3174	probes	abstract[162]|abstract[165]|abstract[166]|object[167]	new[162]|new[165]|new[166]|new[167]	_	_
14-18	3175-3178	for	abstract[162]|abstract[165]|abstract[166]	new[162]|new[165]|new[166]	_	_
14-19	3179-3189	superoxide	abstract[162]|abstract[165]|abstract[166]|substance|abstract[169]	new[162]|new[165]|new[166]|giv|giv[169]	_	_
14-20	3190-3199	detection	abstract[162]|abstract[165]|abstract[166]|abstract[169]	new[162]|new[165]|new[166]|giv[169]	_	_
14-21	3200-3202	in	abstract[162]|abstract[165]|abstract[166]|abstract[169]	new[162]|new[165]|new[166]|giv[169]	_	_
14-22	3203-3207	cell	abstract[162]|abstract[165]|abstract[166]|abstract[169]|animal|abstract[171]	new[162]|new[165]|new[166]|giv[169]|giv|new[171]	coref|coref	14-46|14-46[180_171]
14-23	3208-3215	culture	abstract[162]|abstract[165]|abstract[166]|abstract[169]|abstract[171]	new[162]|new[165]|new[166]|giv[169]|new[171]	_	_
14-24	3216-3217	,	_	_	_	_
14-25	3218-3220	we	person	giv	ana	14-28
14-26	3221-3226	think	_	_	_	_
14-27	3227-3231	that	_	_	_	_
14-28	3232-3235	our	person|abstract[174]	giv|new[174]	_	_
14-29	3236-3243	present	abstract[174]	new[174]	_	_
14-30	3244-3248	data	abstract[174]	new[174]	_	_
14-31	3249-3252	are	_	_	_	_
14-32	3253-3255	of	_	_	_	_
14-33	3256-3264	interest	_	_	_	_
14-34	3265-3268	for	_	_	_	_
14-35	3269-3272	all	person[175]	new[175]	_	_
14-36	3273-3284	researchers	person[175]	new[175]	_	_
14-37	3285-3290	using	person[175]	new[175]	_	_
14-38	3291-3310	hydroethidium-based	person[175]|object[176]|object[177]	new[175]|giv[176]|giv[177]	coref	14-38[177_176]
14-39	3311-3317	probes	person[175]|object[176]|object[177]	new[175]|giv[176]|giv[177]	_	_
14-40	3318-3319	,	person[175]|object[177]	new[175]|giv[177]	_	_
14-41	3320-3323	but	person[175]|object[177]	new[175]|giv[177]	_	_
14-42	3324-3334	especially	person[175]|object[177]|abstract[178]	new[175]|giv[177]|giv[178]	_	_
14-43	3335-3342	mitoSOX	person[175]|object[177]|abstract[178]	new[175]|giv[177]|giv[178]	_	_
14-44	3343-3344	,	_	_	_	_
14-45	3345-3347	in	_	_	_	_
14-46	3348-3352	cell	animal|abstract[180]	giv|giv[180]	_	_
14-47	3353-3360	culture	abstract[180]	giv[180]	_	_
14-48	3361-3362	,	_	_	_	_
14-49	3363-3371	isolated	animal[181]	new[181]	_	_
14-50	3372-3384	mitochondria	animal[181]	new[181]	_	_
14-51	3385-3388	and	_	_	_	_
14-52	3389-3395	tissue	object|object[183]	giv|new[183]	_	_
14-53	3396-3403	samples	object[183]	new[183]	_	_
14-54	3404-3405	.	_	_	_	_
